The Trump administration has signaled potential measures to limit the flow of Chinese-developed experimental medicines to the United States. Official statements suggest a review of import protocols to assess potential risks to American health security. The administration is examining safeguards to protect patients from potential adverse effects associated with these novel treatments. The focus is on ensuring compliance with existing regulations and potential future measures to monitor pharmaceutical supply chains. The exact nature of the crackdown remains to be determined.
Credits: The Straits Times World News